Does CytoSorb Pose Unique Challenges to Pooled Estimates in Meta-Analysis?
- PMID: 37971336
- DOI: 10.1097/CCM.0000000000006043
Does CytoSorb Pose Unique Challenges to Pooled Estimates in Meta-Analysis?
Conflict of interest statement
Dr. Wieruszewski received funding from La Jolla Pharmaceutical Company. Dr. Murad has disclosed that he does not have any potential conflicts of interest.
Comment on
-
The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Crit Care Med. 2023 Dec 1;51(12):1659-1673. doi: 10.1097/CCM.0000000000006007. Epub 2023 Aug 21. Crit Care Med. 2023. PMID: 37607074 Free PMC article.
References
-
- Murad MH, Montori VM, Ioannidis JPA, et al.: How to read a systematic review and meta-analysis and apply the results to patient care: Users’ guides to the medical literature. JAMA. 2014; 312:171–179
-
- Murad MH, Asi N, Alsawas M, et al.: New evidence pyramid. Evid Based Med. 2016; 21:125–127
-
- Heymann M, Schorer R, Putzu A: The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Crit Care Med. 2023; 51:1659–1673
-
- Zeng L, Brignardello-Petersen R, Hultcrantz M, et al.: GRADE Guidance 34: Update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol. 2022; 150:216–224
-
- CytoSorb: CytoSorbents Europe GmbH. Available at: https://cytosorb-therapy.com . Accessed July 17, 2023
Publication types
LinkOut - more resources
Full Text Sources